Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Vitamin C and Reduced Mortality Risk

Research synthesisLow evidenceSmall effect5 studies · 1 beneficial · 4 neutral · 0 harmful

Across 5 studies, 1 reported a beneficial moderate-sized effect of Vitamin C on reducing mortality risk in COVID-19 patients, while 4 studies found neutral small effects, primarily in sepsis populations. The median study duration was only 4 days (from 1 study reporting duration), which is too short to assess long-term mortality outcomes. Most evidence comes from clinical populations with acute critical illness.

  • Studied populations: patients with COVID-19, sepsis, or septic shock

Caveats: Many of the included studies did not reach statistical significance — effect may be smaller than the predominant direction suggests. Evidence base is small (only 5 studies) — conclusions should be considered preliminary. All studies focused on short-term mortality in critically ill patients, not general population mortality. Most studies used Vitamin C as part of combination therapy (e.g., with hydrocortisone and thiamine), making it difficult to isolate the effect of Vitamin C alone.

Generated Jun 11, 2026
Doses used in studies
  • mg/kg/day: 50 (median 50, IQR 5050) 1 study
Time to effect
Median: 4 days · IQR 4 days4 days · Range 4 days4 days — Reported in 1 of 5 studies
Safety in these studies
5 of 5 papers
Back to top